Non-small cell squamous lung carcinoma

This completed Phase 4 trial tested two different doses of chemotherapy (standard and low-dose) combined with the immunotherapy drug Sintilimab in 20 people with advanced squamous non-small cell lung cancer. The goal was to see if the lower-dose combination could shrink tumors an…

This trial is testing whether a blood test called VeriStrat can help choose between two drugs for people with advanced squamous non-small cell lung cancer that has progressed after initial chemotherapy. Participants are grouped by their VeriStrat result (good or poor) and then ra…

This study tests whether a new drug called RPH-075, a biosimilar of pembrolizumab (Keytruda), works as well as the original in people with skin melanoma, lung cancer, or head and neck cancer. Participants receive a single dose of either RPH-075 or Keytruda, and researchers compar…

This phase 3 trial tested whether adding the drug olaparib (Lynparza) to standard treatment with pembrolizumab (Keytruda) and chemotherapy helps people with advanced nonsquamous lung cancer live longer without their disease worsening. Over 1,000 participants received either olapa…

This phase 3 study tested whether adding the immunotherapy drug retifanlimab (INCMGA00012) to standard platinum-based chemotherapy helps people with advanced non-small cell lung cancer live longer. The trial enrolled 583 patients who had not received prior treatment for metastati…

This phase 2 study tested three different drug combinations in 151 people with advanced non-small cell lung cancer that had not been treated before. The drugs help the immune system attack cancer cells. Researchers measured how many patients' tumors shrank or stopped growing, and…

This phase 2 trial tested a drug called patritumab deruxtecan (HER3-DXd) in 63 patients with breast cancer, lung cancer, or other solid tumors that had spread to the brain or the lining of the brain and spinal cord. The drug is designed to seek out and destroy cancer cells carryi…

This study tested whether adding the drug olaparib to standard treatment (pembrolizumab plus chemotherapy) helps people with advanced squamous non-small cell lung cancer live longer or keep the cancer from growing. About 850 adults who had not been treated before took part. The g…

This study tested a new drug, TAK-981, combined with the immunotherapy pembrolizumab in 161 adults with advanced or metastatic solid tumors that could not be cured. The main goals were to check safety and see if the combination could shrink tumors. Participants received treatment…

This study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …